-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on OnKure Therapeutics, Maintains $34 Price Target

Benzinga·08/26/2025 14:34:06
Listen to the news
HC Wainwright & Co. analyst Robert Burns reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Buy and maintains $34 price target.